Publicaciones en las que colabora con Julio Núñez Villota (20)

2024

  1. Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease

    Archivos de Bronconeumologia, Vol. 60, Núm. 4, pp. 226-237

2023

  1. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

    Journal of Clinical Medicine, Vol. 12, Núm. 21

  2. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  3. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  4. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

2022

  1. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2170-2180

  2. Serum potassium dynamics during acute heart failure hospitalization

    Clinical Research in Cardiology, Vol. 111, Núm. 4, pp. 368-379

  3. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1816-1826

2021

  1. Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

    Scientific Reports, Vol. 11, Núm. 1

  2. The pre-HFpEF stage: A new entity that requires proper phenotyping for better management

    European Journal of Preventive Cardiology

2020

  1. Impact of pre-hospital renal function on the detection of acute kidney injury in acute decompensated heart failure

    European Journal of Internal Medicine, Vol. 77, pp. 66-72

  2. Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

    ESC Heart Failure, Vol. 7, Núm. 2, pp. 559-566

2019

  1. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

    JACC: Basic to Translational Science, Vol. 4, Núm. 7, pp. 831-840

2018

  1. Genetic Etiology for Alcohol-Induced Cardiac Toxicity

    Journal of the American College of Cardiology, Vol. 71, Núm. 20, pp. 2293-2302

2017

  1. Early serum creatinine changes and outcomes in patients admitted for acute heart failure: the cardio-renal syndrome revisited

    European heart journal. Acute cardiovascular care, Vol. 6, Núm. 5, pp. 430-440

  2. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure

    European heart journal. Acute cardiovascular care, Vol. 6, Núm. 8, pp. 685-696

  3. Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: The AGTP II trial

    BMJ Open, Vol. 7, Núm. 8

2016

  1. Serum neprilysin and recurrent hospitalizations after acute heart failure

    International Journal of Cardiology, Vol. 220, pp. 742-744

2015

  1. Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure. A Pilot Study.

    JACC: Heart Failure, Vol. 3, Núm. 8, pp. 641-644

2014

  1. Red blood cell distribution width is longitudinally associated with mortality and anemia in heart failure patients

    Circulation Journal, Vol. 78, Núm. 2, pp. 410-418